Wegovy (semaglutide) and Saxenda (liraglutide) are both injectable GLP-1 receptor agonists approved for chronic weight management, but they differ in dosing frequency, average effectiveness seen in trials, and now, formulation options. This guide compares the two directly.
This is general information, not medical advice.
Wegovy vs Saxenda at a glance
| Wegovy (semaglutide) | Saxenda (liraglutide) | |
|---|---|---|
| Active ingredient | Semaglutide | Liraglutide |
| Dosing frequency | Once weekly | Once daily |
| Administration options | Injection, or oral tablet (newer) | Injection only |
| FDA-approved for | Chronic weight management, cardiovascular risk reduction, adolescents 12+, MASH | Chronic weight management, adolescents 12-17 |
| Initial approval | 2021 | 2014 |
Both are GLP-1 receptor agonists, but different molecules
Semaglutide (Wegovy) and liraglutide (Saxenda) are both GLP-1 receptor agonists that work by mimicking the natural GLP-1 hormone, increasing insulin secretion, decreasing glucagon, slowing gastric emptying, and acting on brain appetite centers. They are different molecules, however, not the same drug at different doses (unlike the Saxenda/Victoza relationship, which does share one molecule). Semaglutide has a longer half-life, which is why Wegovy is dosed weekly, while liraglutide’s shorter half-life requires Saxenda’s daily dosing schedule.
Dosing frequency: a real practical difference
Wegovy is injected once weekly, a substantially more convenient schedule for many patients, requiring far fewer injections over the course of a month than a daily regimen.
Saxenda requires a daily injection, which some patients find more burdensome long-term, though the once-daily routine can also feel more manageable to establish as a habit for others, so this isn’t universally a downside for everyone.
Effectiveness differences seen in trials
Across published trial data and comparative reviews, semaglutide (Wegovy) has generally demonstrated greater average weight loss than liraglutide (Saxenda) in comparable populations, part of why semaglutide products have become more prominent in current obesity treatment discussions. This doesn’t mean Saxenda is ineffective, individual response varies significantly, and some patients do better on one than the other, but population-level trial averages have generally favored semaglutide’s newer mechanism refinements.
The newer oral option
As of 2025, an oral Wegovy tablet became available in addition to the original injection, the first needle-free semaglutide weight-loss option. Saxenda remains injection-only; there is no oral liraglutide product for weight management currently available in the same way.
Side effects
Both share the class-wide GLP-1 side effect profile: nausea, vomiting, diarrhea, and constipation, generally the most commonly reported adverse effects for both drugs, tied to their shared effect on gastric emptying. Both carry the same boxed thyroid C-cell tumor warning based on rodent studies, with human relevance undetermined, a warning that spans the entire GLP-1 drug class regardless of specific molecule.
Who each might suit
Factors that may point toward Wegovy:
- A preference for weekly rather than daily injections
- Generally larger average weight loss seen across comparative trial data
- A need for the cardiovascular risk-reduction indication or the newer oral tablet option
Factors that may point toward Saxenda:
- A longer track record (approved since 2014, versus Wegovy’s 2021) with correspondingly more accumulated real-world use
- Prior good tolerance and response specifically to liraglutide
- A prescriber or insurance formulary preference for liraglutide specifically
Frequently asked questions
Are Wegovy and Saxenda the same drug?
No. Wegovy contains semaglutide; Saxenda contains liraglutide. They’re different molecules in the same drug class (GLP-1 receptor agonists), not the same drug at different doses.
Which requires fewer injections?
Wegovy, dosed once weekly, versus Saxenda’s once-daily injection schedule.
Which produces more weight loss?
Trial data has generally shown greater average weight loss with semaglutide (Wegovy) than liraglutide (Saxenda) in comparable populations, though individual results vary.
Is there a pill version of either?
Yes, for Wegovy specifically, an oral tablet became available in 2025 alongside the original injection. Saxenda does not have an equivalent oral weight-management product.
Do both cause nausea?
Yes, nausea, vomiting, diarrhea, and constipation are common with both, tied to their shared effect on slowing gastric emptying.